YIH
MRTX

Y-Intercept (HK)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Y-Intercept (HK)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,819
Closed -$455K – 978
2021
Q2 		$455K Buy
+2,819
New +$453K 0.12% 288
2021
Q1 		– Sell
-1,280
Closed -$281K – 862
2020
Q4 		$281K Buy
+1,280
New +$277K 0.12% 333

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Y-Intercept (HK)'s MRTX Position: Q3 2021 in Review

Y-Intercept (HK) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 2,819 shares — an estimated $455K sold.

Y-Intercept (HK) first reported a position in MRTX in Q4 2020 and held it in 2 quarters. The position peaked at $455K in Q2 2021. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • Y-Intercept (HK) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Y-Intercept (HK) sold 2,819 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $455K.
  • Y-Intercept (HK) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Y-Intercept (HK)'s Mirati Therapeutics, Inc. Common Stock position peaked at $455K in Q2 2021.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Y-Intercept (HK)'s 13F filing for Q3 2021, filed 15 Nov 2021.